NCT00741767View on ClinicalTrials.gov

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NAWithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

February 29, 2012

Conditions

Chronic Obstructive Pulmonary DiseaseSleep Disorders

Interventions

DRUG

salmeterol-fluticasone

250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Northwestern University

OTHER

NCT00741767 - The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD | Biotech Hunter | Biotech Hunter